AHA
<ѻý class="page-description">American Heart Associationѻý>Intervention trial shows impact that could pay off long-term
Monoclonal antibody promises substantial lipid lowering with just one injection every 3 months
Huge trial from China reinforces the message from SPRINT for higher-risk hypertensive patients
But whether the small absolute gain shown in ARTESiA is worth the bleeds is another question
Preliminary data support concept of "molecular surgery" on PCSK9 gene
Benefit finally proven in clinical trial
Clinical trial affirms a better initial strategy
Dietary change produces clinically relevant BP changes within a week
Warfarin does a good enough job alone without adding aspirin
Reduced angina frequency with anti-anginal meds out of the picture
For patients with anemia, trial suggests the commonly used restrictive strategy might not be best
Established weight loss and diabetes drug may extend reach to millions more
Surgical revascularization better for limb events and death when an adequate vein was available
Novel agent shortened episodes versus placebo
-
AHA: American Heart Association
November 2024
-
TCT: Transcatheter Cardiovascular Therapeutics
October 2024
-
HFSA: Heart Failure Society of America
September 2024
-
ESC: European Society of Cardiology Congress
August 2024